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We earlier reported that immunization of macaques with a reverse transcriptase-deleted SHIVKU2 (ΔrtSHIVKU2) plasmid that contained HIV-1
(HXB2) env and SIV gag–nef induced protection against AIDS caused by challenge virus SHIV89.6P with a heterologous env. We further deleted
vif and integrase from ΔrtSHIVKU2 and substituted the 3′LTR with SV40 poly A sequences, creating Δ4SHIVKU2 (M) and a parallel construct
containing gag–nef of HIV-1SF2, Δ4SHIVKU2 (H). Six macaques received two intramuscular injections of the (M) DNA, and another six received
three injections of the (H) DNA. Three of the latter group received two post-challenge boosts with (M) DNA vaccine. Seven virus control
macaques were inoculated with SHIV89.6P. All twelve immunized macaques were challenged with SHIV89.6P virus, and CMI responses were
measured by ELISPOT assays.
Virus control animals all developed progressive infection, whereas vaccinated macaques from both groups controlled virus replication, with
plasma viral loads dropping to undetectable levels between weeks 6 and 126 p.i. This DNA vaccine was efficacious even though it encoded Env,
Gag, and Nef that were genetically distinct from the proteins in the challenge virus. The DNA vaccine induced broad-based protection without
using viral proteins to boost the immunity.
© 2006 Elsevier Inc. All rights reserved.Keywords: DNAVaccines; Macaque; AIDS; SHIVIntroduction
The availability of a safe and effective vaccine to prevent
AIDS remains an elusive goal and thus necessitates various
approaches to the problem. The use of live-attenuated simian
immunodeficiency virus (SIV) and chimeric SIV/human
immunodeficiency virus (SHIV) viruses in the macaque
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doi:10.1016/j.virol.2006.03.033virus replication can be controlled for long periods of time in
infected individuals to halt disease progression. The concept of
using live-attenuated vaccines for HIV-1 however was aban-
doned for safety reasons and also because the immunity induced
by the live SHIV vaccines was contingent on persistent
infection by the vaccine virus. Challenged immunized maca-
ques that subsequently eliminated their vaccine virus suc-
cumbed to AIDS caused by resurgent challenge virus that had
been maintained in a latent state in the presence of persistent
vaccine virus (Mackay et al., 2004). Thus, the live SHIV
vaccines likely did not induce memory immune responses.
The use of plasmid DNA encoding HIV-1 genes as a
vaccine has proven an excellent alternative to live vaccines
because they induce memory CMI responses, the arm of the
immune response that is closely associated with control of the
virus (Letvin et al., 1997, 1998; MacGregor et al., 2002;
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Yasutomi et al., 1996). Most of the current DNA vaccines
utilize either CMV (Tang et al., 1992), β-actin, or muscle-
specific desmin promoter (Cazeaux et al., 2002) to drive
expression of one or two fused genes of HIV-1 including the
env, gag, pol (Amara et al., 2001; Amara et al., 2002a; 2002b),
and tat (Ensoli and Cafaro, 2000). DNA vaccines comprised of
multiple plasmids encoding different HIV-1 proteins have been
used to obtain a broader spectrum of immunity than individual
plasmids expressing single proteins (Kong et al., 2003). The
use of these plasmid DNA vaccines proved to be safe and
immunogenic in macaques, but nevertheless required boosts
with viral proteins (Letvin et al., 1997), or viral proteins
expressed by various vector systems including recombinant
pox virus (Robinson et al., 2000), modified vaccinia virus
Ankara (Amara et al., 2002a; Barouch et al., 2001; Earl et al.,
2002), and adenovirus (Casimiro et al., 2003; Kostense et al.,
2004) to be efficacious in preventing AIDS.
Because of potential logistical problems involved with
prime/boost strategy in carrying out vaccination in underde-
veloped countries, we undertook studies to explore whether a
new type of DNA vaccine could be efficacious without the
need for viral protein boosts. In an earlier report, we had
shown that the genes of SHIVKU2, a virus known for its high
replication efficiency in macaques, could be used as a
vaccine after the genome was made non-infectious by
deletion of the RT portion of the pol gene (Singh et al.,
2005). We also showed that inoculation of mice in the
gastrocnemius muscle with a noninfectious ΔRT Δint Δvif
SHIV construct resulted in the production of viral p24 in
myocytes and infiltrating mononuclear cells (Hegde et al.,
2005). In the current study, we report that after additional
deletions of integrase and vif and substitution of SV40 poly
A sequences for the 3′LTR, the genome of SHIVKU2, still
remained immunogenic and efficacious in macaques. The
Δ4SHIVKU2 DNA utilized promoter/enhancer sequences in
the 5′LTR of SIVmac239 to drive expression of Gag,
Protease, Vpr/Vpx, Tat, Rev, Vpu, Env, and Nef. The gag,
env, and nef could be exchanged by genetic engineering
techniques from those of SIV to those of HIV-1. The DNA
was incorporated into a plasmid and tested for expression in
transfected cell cultures prior to immunization of cynomolgus
macaques by intramuscular injections of the DNA. In this
study, we used two constructs, Δ4SHIVKU2 (M) (M DNA)
and Δ4SHIVKU2 (H) (H DNA), respectively, to immunize
macaques to explore the breadth of the protective antiviral
responses by using SHIV89.6P that has the SIV gag–nef as
challenge. The first vaccine construct (M) utilized the
macaque adapted env of HIV-1 HXB2, thereby providing a
heterologous env gene. The gag–nef genes of the (M) DNA
were similar to those of the challenge virus. The second
construct (H) contained the gag–nef of HIV-1SF2, thereby
obtaining a DNA molecule that encoded distinctly different
env, gag, and nef genes from corresponding proteins of the
challenge virus. Macaques prophylactically immunized with
either construct were protected from persistent productive
replication of the challenge virus. These results indicated thatthis type of vaccine that facilitated synthesis of several HIV-
1 proteins in a part of a single cycle of replication of the
virus has the potential for eliciting broad-based protection
and, importantly, that protection could be obtained without
need for using viral proteins to boost immunity.
Results
The construction of the gene-deleted DNA vaccines
Δ4SHIVKU2 (M) [(M) DNA] and Δ4SHIVKU2 (H) [(H)
DNA] is shown diagrammatically in Fig. 1. These constructs
are based on the backbone of SIVmac239 and lack the RT,
integrase, vif, and 3′ LTR. The env genes are derived from HIV-
1 HXB2, and the gag, pro, and nef are from SIVmac239 and
HIV-1SF2, respectively. The SV40 polyadenylation signal was
cloned in 3′ to the nef gene.
Transfection of (M) and (H) DNAs resulted in transient
expression of viral proteins in HEK293
Human HEK293 cells were transfected with the constructs
using a standard protocol reported earlier Hegde et al., 2005.
Transfected cells were monitored through day 14 for the
production of p27 or p24. Protein was prepared from
harvested cells in a parallel culture incubated with [35S]
methionine and cysteine, and proteins were immunoprecipi-
tated and separated by SDS polyacrylamide gel electropho-
resis. The immunoprecipitation study showed that the plasmid
DNAs expressed gp160, gp120 and p55, p27/p24, Gag-pol,
and Gag of both constructs (Fig. 2A), with peak production of
the Gag protein at concentrations of 30–40 ng/ml between
day 2 and 4 (Fig. 2B). Supernatant fluids and lysates of
transfected cells were examined for infectivity in Jurkat cell
cultures that are highly susceptible to replication and
development of CPE caused by SHIVKU2. These inoculated
cultures did not develop CPE, and PCR for gag in cell lysates
was negative (data not shown).
Macaque infection with SHIV89.6P−CY
All seven control macaques inoculated with the challenge
virus, SHIV89.6P−CY, developed highly productive infections
within 2 weeks after inoculation; plasma viral RNA
concentrations peaked at levels varying from 4 × 107 to
3 × 109, with set points varying from approximately 104 to
106 copies/ml plasma (Figs. 3A, B). Four of the seven
animals developed a precipitous loss of CD4+ T cells by
3 weeks after inoculation, and this was maintained in all four
to the end of the study at week 135. Three animals retained
CD4 counts above 200 until weeks 59–93 p.i. One animal,
13-1030, maintained a count of 586 CD4+ T cells/ml blood
(Fig. 3C). Except for this animal, all of others developed
minimal ELISPOT titers (Fig. 3D). Four of the seven animals
died with AIDS at various points during the observation
period as indicated in Fig. 3B. Note that the groups of
animals were not infected simultaneously, thus the numbers of
weeks post-infection vary in the figures. Of the three
Fig. 1. Schematic diagram illustrating sequential steps in the construction of Δ4SHIVKU2 DNA vaccines, (M) and (H), with (M) containing the gag and nef of SIV
origin and env from HIV-1 and (H) containing the gag, env, and nef of HIV-1SF2. Detailed descriptions of the cloning steps are given in Materials and methods.
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maintained viral RNA concentration in excess of 104 copies/
ml plasma, CD4+ T cell counts less than 100 cells/ml blood,
and negligible ELISPOT responses. Thus, these two animals
are at risk for developing AIDS. Macaque 13-1030 is the only
member of the group that has maintained relative control over
the virus. Nevertheless, this animal has a viral RNA
concentration of almost 10,000 copies/ml plasma.
Immunization of six macaques with Δ4SHIVKU2 (M)
The six animals immunized with DNA expressing SIV
Gag–Nef developed ELISPOT responses to SIV Gag
peptides, and were challenged with SHIV89.6PCY between
5 and 12 weeks after the last boost (Fig. 4A). Following
challenge, all animals became infected, with viral RNA titers
peaking a week later at concentrations varying from 103 to
107 copies/ml (Fig. 4B). However, these titers declined
rapidly, and viral RNA became undetectable in individual
animals between week 6 and 126. All of the animalscontrolled plasma virus to less than 3000 viral RNA copies/
ml by weeks 2–40 (Fig. 4B).
ELISPOT responses surged 1 week following challenge and
levels fluctuated in individual animals as shown in Fig. 4A. The
ELISPOT responses in general declined during the following 64
weeks. Three of the animals became negative at this point in
contrast to the other three that had responses of 170–400 at
week 98 (Fig. 4A). None of the animals developed any
significant loss of CD4+ T cells (Fig. 4C). Thus, the vaccine
protected all of the animals from AIDS, with viral RNA in
plasma becoming undetectable in five of the six animals within
1 year after challenge (Fig. 4B).
Immunization of six macaques with (H) DNA
In the preceding experiment, we showed that the (M)
DNA induced protection against a virus with a different
Env, but homologous Gag–Nef. In the experiment reported
below, we sought to determine whether the vaccine with
HIV-1 gag–nef genes would elicit protection against
Fig. 2. Production of viral proteins from DNA vaccine constructs. (A)
Immunoprecipitation data showing viral proteins encoded by vaccines (H)
and (M) that were secreted into the supernatant fluid (S) and present in cell
extracts (C) of transfected HEK293 cells. HEK293 cells were transfected with
4.75 μg of vaccine construct and 15.5 μl of ExGen 500. At day 2 p.i., proteins
were extracted from cell lysates and supernatant fluids using protein A
Sepharose (catalog number 17-0780-01, Amersham Bioscience AB, Sweden)
and normal and immune human or macaque sera used to precipitate various
proteins. The immunoprecipitates were separated by SDS-polyacrylamide
electrophoresis in 10% gels, dried, and exposed to X-ray film. Lanes 1, 2,
uninfected cells; lanes 3, 4, cells infected with Δ4SHIVKU2(H); lanes 5, 6, cells
infected with Δ4SHIVKU2(M). C, cell-associated proteins; S, supernatant
proteins. (B) Quantification of Gag p27 of the (M) construct and p24 of the (H)
construct secreted into the supernatant fluids of transfected HEK293 cells.
Samples of supernatant medium were harvested at the indicated times. ELISAs
were performed on the fluids and standards, and the p24 or p27 concentrations
were determined by regression from the standard curves. The transfected cells
were rinsed three times following harvest of fluids at each sampling period.
Thus, the reported values represent the amount of viral proteins secreted into the
supernatant fluids during the previous 24 h.
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immunized three times within a 36-week period and
challenged 4 weeks after the third immunization. All six
animals became infected with the challenge virus, with viral
RNA concentrations peaking between 5 × 106 and 5 × 108
copies/ml during the first 3 weeks after challenge. These
values declined after this period (Figs. 5A and 6A).
The six animals had developed ELISPOT responses by
3 weeks post-challenge as shown in Figs. 5B and 6B. At
this point, we elected to determine whether administration of
vaccine DNA in the presence of active virus replication
would result in enhancement of virus replication, or a more
rapid decline in virus replication. We therefore arbitrarily
divided the animals into two groups of three and
administered the (M) DNA to one group (Fig. 5). The
DNA was administered at weeks 6 and 13 post-challenge.The second group received no post-challenge immunizations
(Fig. 6).
Plasma viral RNA concentrations in the six animals
remained high for only 3 weeks after which the concentrations
declined about 1000-fold (Figs. 5A, 6A), irrespective of
whether or not the animals were re-immunized. All six animals
developed complete control of the challenge virus, becoming
viral RNA negative between weeks 19 and 86. There was no
significant difference between the two groups in the rate of viral
RNA decline in plasma (Figs. 5A, 6A).
The CD4+ T cell counts in the six animals declined following
challenge but have remained above 500 cells/ml at 2 years post-
challenge (data not shown).
Discussion
Previously, we reported that a plasmid DNA vaccine
ΔrtSHIVKU2 containing SIV gag–nef and HIV-1 env,
regulated by the SIV promoter, induced protection in
macaques from AIDS, without need for pre-challenge boosts
with vectors expressing viral proteins (Singh et al., 2005).
Although we did not detect infectious virus either in
transfected HEK cells or in PBMCs of ΔrtSHIVKU2-injected
macaques, that construct still had integrase, vif, and 3′LTR
sequences and thus retained the potential for integration and
re-acquisition of infectivity by recombination. We undertook
the study reported here to determine if further deletion of vif
and integrase genes and substitution of the 3′LTR with SV40
poly A sequences could be performed without affecting the
immunogenicity or efficacy of the DNA in inducing
protection against AIDS caused by a heterologous virus.
Since env, gag, tat, rev, vpu and nef have all been shown to
be important for induction of protection against AIDS (Amara
et al., 2001, 2002b; Ensoli and Cafaro, 2000; MacGregor et
al., 2002; Singh et al., 2005), we retained these genes in both
of the constructs used in this study. We tested both for
infectivity and kinetics of viral protein production in
transfected cell cultures and showed that the DNA expressed
all of the viral proteins with kinetics similar to that of parental
virus SHIVKU2, but as expected, they did not produce
infectious particles.
SHIV89.6P−CY was chosen as the challenge virus because
it has dual tropism for the CXCR4 and CCR5 co-receptors
used by HIV-1. Furthermore, this virus contains several of the
HIV-1 proteins that make it relevant to study of HIV-1
pathogenesis. In its normal pathogenesis, SHIV89.6P causes
rapid elimination of naive CD4+ T cells present in peripheral
blood and lymph nodes, and later, the memory CD4+ T cells
present in the gut-associated lymphoid tissues, spleen and
lungs. In unpublished studies, animals that were partially
protected against this virus were spared the precipitous loss of
the naive CD4+ T cells but succumbed to the slower disease
with maintenance of high viral RNA concentrations in
plasma. In the study reported here, the seven unvaccinated
macaques challenged with this virus developed the typical
precipitous loss of naive CD4+ T cells from the blood, and
this was maintained in four of the seven animals. One animal
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Fig. 4. (A) Pre- and post-challenge ELISPOT responses in macaques immunized with vaccine (M) DNA are presented as spot-forming cells (SFC) per million PBMC
at weeks post-inoculation. (B) Plasma viral concentrations in macaques immunized with vaccine (M) DNA are presented as viral RNA copy numbers per ml plasma at
weeks post-inoculation. (C) CD4+ T cell counts in vaccine (M) animals indicated by number of cells per μl blood. A horizontal line is shown at the level of 1000 CD4
cells per μl. For all graphs, the solid arrow represents the time of virus challenge.
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the vaccinated animals resisted loss of naive CD4+ T cells,
and at the end of the study in which all 12 challenged
vaccinates remained healthy, all animals have greater than
796 cells/ml blood and negligible viral RNA in plasma at
2 years p.i.
The vaccines induced ELISPOT responses against pep-
tides primarily in the Gag (SIV and HIV-1) in all of the
twelve of the macaques that were immunized with the
DNAs. The responses increased 5- to 20-fold following
challenge and were associated with suppression of replica-
tion of the challenge virus. Decrease in virus replication was
continuous. In the six animals immunized with the (M)
DNA, viral RNA in plasma became undetectable by RT-
PCR in four of the six by weeks 6–35, and in the other
two, by week 92–126. There was a minimal loss of CD4+ TFig. 3. (A, B) Plasma viral RNA concentrations determined by real-time RT-PCR are p
virus control animals. Plasma viral RNA set points remained >104 copies per ml throu
Beckton-Dickinson FACSCalibur flow cytometer and are represented as CD4+ T c
indicated time points.cells during this period. These protective effects were a
dramatic contrast to the virus control group.
Since it would be important to have a vaccine that could
induce cross-clade protection, we decided to test immuno-
genicity of a construct expressing HIV-1 Gag–Nef in
addition to the heterologous Env. This construct, (H)
DNA, was used to immunize six macaques. Although all
six became viremic following challenge with SHIV89.6P,
three that were observed for the next several weeks
developed a similar level of control of the challenge virus
as the six animals that were immunized with the (M) DNA.
In order to determine whether the vaccine could be
administered safely to animals that were still viremic, and
if vaccine would decrease viremia more rapidly, two doses
of (M) DNA were administered sequentially to three of the
six vaccinates. First, there was no evidence that the vaccineresented as viral RNA copy numbers per ml plasma at weeks post-inoculation in
ghout the study period in all seven animals. (C) CD4+ T cell counts assayed in a
ells per μl blood. (D) ELISPOT cells were detected per million PBMCs at the
Fig. 5. (A) Plasma viral RNA concentrations in three macaques immunized with (H) DNA, challenged with SHIV89.6P−CY, and given two post-challenge
immunizations with (M) DNA. Immunizations are indicated by open arrows and challenge by solid arrow. (B) ELISPOT responses in the same macaques, represented
by spot-forming cells per million PBMCs. Immunizations are indicated by open arrows, and challenge by solid arrow.
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three that received the post-challenge immunization com-
pletely controlled replication of challenge virus with
approximately the same kinetics as the three that did not
receive post-challenge immunizations. None of the animals
developed AIDS nor did they lose CD4+T cells since all six
maintained cell counts above 500 per ml and showed
undetectable viral RNA in plasma by week 135 post-
challenge. Since most of the ELISPOT responses in
immunized macaques were directed against Gag, protection
induced by DNA encoding HIV-1 Gag–Nef against
SHIV89.6P virus that contains an SIV gag–nef illustrated
the breadth of efficacy of this type of vaccine DNA. Recent
studies have shown that HIV-1 Gag has conserved cross-
clade CD8 and CD4 epitopes that are recognized by
humans and macaques (Amara et al., 2005). Efficacy of the
(H) DNA, encoding gag–nef genes that were different from
the challenge virus, corroborates this report.
In summary, data shown in this report indicate that a
Δ4SHIVKU2 DNA construct that expresses six proteins of the
lentivirus under the lentiviral promoter has the potential for
eliciting protection against challenge virus containing heterol-ogous env, gag, and nef genes and that this protection could be
induced by using the DNA alone without need for supplemental
boosts with viral proteins.
Materials and methods
Cells and viruses
Human embryonic kidney 293 (HEK293) cells were used
to assess protein expression capability of the Δ4SHIVKU2
construct. These cells were also used to determine kinetics
of production of viral Gag protein. Jurkat cells were used to
test infectivity of this construct and were maintained in
RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemen-
ted with 10 mM HEPES buffer, pH 7.3, 2 mM glutamine,
5 μg/ml of gentamicin, and 10% fetal bovine serum.
HEK293 cells were maintained in DMEM supplemented
with 10 mM HEPES buffer, pH 7.3, 2 mM glutamine, 5 μg/
ml of gentamicin, and 10% fetal bovine serum.
SHIV89.6P was obtained from Dr. Norman L. Letvin and
was passage-adapted in our laboratory in cynomolgus
monkeys (SHIV89.6P−CY). The virus adapted in cynomolgus
Fig. 6. (A) Plasma viral RNA concentrations in three macaques immunized with (H) DNA followed by challenge with SHIV89.6P−CY. Immunizations are indicated by
open arrows, and challenge by solid arrow. (B) ELISPOT responses in the same macaques. Immunizations are indicated by open arrows, and challenge by solid arrow.
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This cynomolgus-adapted virus (SHIV89.6P−CY) can utilize
the CCR5 co-receptor very well in culture, as shown by
assays on Ghost cell Hi-5 cells (data not shown; Smith et
al., unpublished). Stocks of the viruses were prepared in
concanavalin-A-treated, CD8 T cell-depleted macaque
PBMC cultures and stored frozen at −80 °C and in liquid
nitrogen.
Construction of Δ4SHIVKU2(M) plasmid DNA that contained
HIV-1 (HXB2) env and SIV gag and nef and Δ4SHIVKU2(H)
that contained the same genes of (M) except for the gag and nef
of HIV-1SF2
The construction procedures of SHIVKU2 plasmid DNA
have been described earlier (Liu et al., 1999), and
sequences have been submitted to GenBank (GenBank
data base accession number AY751799). Construction of
ΔrtSHIVKU2 has been described previously Singh et al.,
2005. This plasmid was used to derive Δ4SHIVKU2 (M)
that contains HIV-1 (HXB2) env and SIV gag–nef and
another construct Δ4SHIVKU2 (H) that contains HIV-1SF2
gag–nef (Fig. 1).The deletion of integrase and vif from ΔrtSHIVKU2 was
performed in two steps. First, a BstEII site was created
immediately before the start codon of vpx gene at nucleotide
position 5042. A PCR fragment was amplified from this
plasmid using the forward primer 5′-GGTCACCATGTCA-
GATCCCAGGGAGAG-3′ at the position 5042–5068 (the
bold letters represent the created BstEII restriction site) and
reverse primer 5′-CTCTTAATTTGCTAGCTATCTG-3′ at
the position 7125–7146 (the bold letters represent the
NheI site of ΔrtSHIVKU2). This produced a fragment of
2089 bp that was used below. In second reaction, a 3817 bp
fragment starting from BstEII site in pol gene at nucleotide
position 3316 to NheI site at position 7132 was replaced by
the 2089 bp fragment from the first step. Next, a series of
PCR and cloning steps were performed to substitute the 3′
LTR with SV-40 poly A sequences. Briefly, a 2337 bp PCR
fragment was amplified from ΔrtSHIVKU2 using the forward
primer 5′-GCTAGCAAATTAAGAGAAC-3′ at the position
7131–7149 (bold letters represent the original NheI site) and
reverse primer 5′-GTCGACTCAGCGAGTTTCC-3′ at the
position 9452–9470 (bold letters represent the created SalI
site). This fragment contained the nef and part of the env of
ΔrtSHIVKU2. Next, the 2743 bp fragment starting from the
452 Z. Liu et al. / Virology 351 (2006) 444–454NheI site at position 7132 encompassing part of env, nef,
and 3′ LTR was substituted by the 2337 bp PCR fragment
lacking the 3′LTR from the previous step.
The sequences for the vector were derived from plasmids
pET-9a (Novagen, San Diego, CA) and pCMV-Tag2 (Strata-
gene, La Jolla, CA). The 1.8 kb BamHI–XmmI fragment of pET-
9a was substituted by the 547 bp BamHI–SspI fragment of
pCMVtag2, such that the resultant 2.5 kb plasmid contained the
SV40 polyadenylation signal sequences and kanamycin resis-
tance gene in the final clone.
Construction of Δ4SHIVKU2 (H) plasmid DNA that contained
HIV-1SF2 gag–nef
To replace SIV gag and protease genes with those of HIV-
1SF2, PCR was performed using forward primer 5′-AATCTC-
TAGCAGTGGCGCCCGAAC-3′ at position 640 (the bold
letters represent the original NarI site of HIV-1SF2) and reverse
primer 5′-GCTGGTGACCCTTTCCATCCCTG-3′ at position
3007 downstream of HIV-1SF2 protease coding sequences (bold
letters represent the BstEII site created by site-directed
mutagenesis). This 2368 bp NarI–BstEII PCR fragment was
used to replace the corresponding 2486 bp NarI–BstEII
fragment of Δ4SHIVKU2 (M). These positions are mentioned
with reference to GenBank database accession number
K02007).
To substitute SIV nef with that of HIV-1SF2, a series of
PCR and cloning steps were used. Briefly, an intermediate
containing part of SHIVKU2−gp41 was made using the
forward 5′-GTGAACGGATCCTTGGCAC-3′ (bold letters
represent the original BamHI site) and reverse 5′-GATATCT-
TATAGCAAAATCCTTTCC-3′ (bold letters represent the
created EcoRV site) primers. The resulting PCR fragment
was cloned into pGEM-T (Promega). The HIV-1SF2 nef was
amplified by PCR in a 1.4 kb fragment containing a NotI site
at the 5′ end and SalI at the 3′ end, using the forward 5′-
GCGGCCGCATGGGTGGCAAGTGGTC-3′ and reverse 5′-
GTCGACTCAGCAGTCTTTGTAGTAC-3′ primers. The
HIV-1SF2 nef was then fused at the end of SHIVKU2-gp41.
The 1 kb BamHI–SalI fragment of this clone was used to
replace that of Δ4SHIVKU2 (M). The resultant construct
Δ4SHIVKU2 (H) contains the gag, pro, partial rt, and nef of
HIV-1SF2.
Transfection studies
Transfection of HEK293 cells with the (M) and (H) DNAs
was carried out using a cationic polymer polyethylenimine
(ExGen 500, MBI Fermentas, Hanover, MD) according to the
manufacturer's instructions. Approximately, 1–3 × 105 cells/
well in six-well plates were transfected with 4.75 μg of vaccine
DNA and 15.5 μl of ExGen 500, corresponding to 6 equivalents.
Culture supernatant fluids were assayed on days 1 and 2, and
every 2 days thereafter, until day 14, to assess kinetics of
synthesis and duration of production p27 or p24. Another set of
transfected cultures was used for immunoprecipitation of
different viral proteins.Quantitation of p27/p24 in the supernatant fluids of transfected
cultures
Supernatant fluids were analyzed by a capture enzyme-
linked immunosorbent assay (ELISA) kit (Coulter Laboratories,
Hialeah, FL) for quantification and duration of secretion of the
two Gag proteins. A standard curve was prepared for each assay
according to manufacturer's instructions, and p27/p24 concen-
trations were determined from the OD450 using linear regression
analysis.
In vitro infectivity assay
Supernatant fluids from transfected HEK293 cells were
harvested on days 2, 4, and 6 after transfection, and 1 ml of the
fluid was inoculated into three cultures of Jurkat cells. The
inoculated cultures were incubated at 37 °C and observed for
the development of fusion cytopathic effects (CPE). At 10 days,
supernatant fluids were tested for the presence of viral p27, and
cell lysates were analyzed for viral DNA by PCR. Infectious
SHIVKU2 DNA-transfected Jurkat and HEK293 cells served as
positive controls in this experiment.
Analysis of inoculated Jurkat cells for viral DNA
DNA was extracted using Qiagen DNA reagents (Valencia,
CA) from Jurkat cells 2 days after transfection and from PBMCs
of immunized macaques a few days after each immunization.
DNA copy numbers were determined by real-time PCR using
SIVmac239-derived gag primers and Taqman probe (Hofmann-
Lehmann et al., 2000; Smith et al., 2002) and the Taqman
Universal PCR Mastermix (Applied Biosystems, Foster City,
CA) in duplicate 25 μl reactions in the ABI PRISM 7700
Sequence Detection System. Proviral copy numbers were
normalized to the quantity of total cellular DNA used in the
reaction. DNA real-time conditions were as described Smith et
al., 2002. Serial 10-fold dilutions of cloned SHIV gag plasmid
over six orders of magnitude were used as standards. The
minimum detectable level of proviral DNA was 30 copies.
Radio-immunoprecipitation assay
We analyzed transfected cultures by standard radio-immu-
noprecipitation of 35S-labeled proteins using normal macaque
and human sera as controls and serum from an SIV-infected
macaque and an HIV-infected person as sources of antiviral
antibodies. Autoradiographs were analyzed for the presence of
different bands corresponding to Env gp160, gp120, gp41, and
Gag p55 and p27/p24.
Immunization of macaques with (M) DNA and challenge with
SHIV89.6P−CY
Nineteen cynomolgus macaques were used in this study. The
animals were prescreened serologically for SIV and STLV and
individually housed at an Association for Assessment and
Accreditation of Laboratory Animal Care-International
453Z. Liu et al. / Virology 351 (2006) 444–454accredited facilities of the University of Kansas Medical Center
and maintained in accord with the guidelines of the Guide for
the Care and Use of Laboratory Animals (National Research
Council, National Academic Press, Washington, DC, 1996).
Animals were divided in three groups. The first group of six
macaques received 5 mg of (M) DNA, IM, twice, 11 weeks
apart. The vaccine plasmid DNAwas suspended in 1 ml of PBS
and injected at two sites. The second group of six macaques was
injected three times with the same amount of (H) DNA. Three
macaques from this group received two post-challenge boosts of
5 mg of (M) DNA at 8 weeks and 13 weeks. Seven animals in
the third group served as non-vaccinated virus controls. All
animals were challenged with SHIV89.6P−CY using 1 ml of
stock virus containing 104 TCID, given IV. This virus uses
CCR5 well in Ghost cell assays and, as expected, can replicate
in both normal human donor and Δ32CCR5 human PBMCs
(M. Smith et al., unpublished). It has been widely used as the
challenge virus in macaques vaccinated with plasmid DNA and
other agents. While this virus can cause rapid CD4 loss after
macaque infection, thus providing a rapid assessment of vaccine
efficacy, we use it with the caveat that it may not recapitulate all
aspects of solely CCR5-tropic HIV-1 in primary human
infection. Animals were analyzed for CMI, CD4+ T cell counts,
and viral RNA copies in plasma.Processing of blood and serum samples
Peripheral blood collected in EDTA was centrifuged to
separate plasma and buffy coat. Plasma samples were immedi-
ately stored at −80 °C for later measurement of viral RNA
concentrations using real-time RT PCR. PBMCs were purified
from buffy coats by centrifugation through Ficoll-Paque density
gradients. Portions of the cells were used for flow cytometry
(FACS), detection of viral DNA by PCR, and ELISPOT assays,
respectively.Assessment of plasma viral RNA concentration using
quantitative real-time RT-PCR analysis
Plasma viral RNA concentrations were measured from RNA
extracted from 800 to 1000 μl of plasma samples as previously
described (Mackay et al., 2002; Smith et al., 2002). RNA
samples were subjected to real-time RT-PCR using gag primers
and a 5′FAM- and 3′TAMRA-labeled Taqman probe measuring
SIVmac239 gag, as described by Hofmann-Lehmann et al.
(2000) and Smith et al. (2002).FACS analysis
PBMCs from vaccinated and control macaques were
subjected to FACS analysis at different time intervals for
quantitation of CD3+, CD4+, and CD8+ T-cells as described
earlier (Kumar et al., 2001). Briefly, 5 μl of a 3-color anti-CD3+,
-CD4+, and -CD8+ antibody mix (Becton-Dickinson, Ruther-ford, NJ) was added to 100 μl of whole blood and incubated for
60 min in the dark. Lysing solution (Becton-Dickinson) was
then added, and the samples were incubated for another 20 min
at room temperature. Stained cells were fixed with 1% formalin
and analyzed in a Becton-Dickinson FACSCalibur flow
cytometer.
ELISPOT assay
We used a quantitative ELISPOT assay that measured IFN-γ
production by PBMC responding to groups of overlapping 15-
mer peptides, with 11 amino acid overlaps, spanning the entire
molecule of selected viral proteins. We used the following
peptide groups represented in SHIV and constructs: HIV-1-Env
(MN) (Cat. No. 6451), consensus HIV-1 Tat (Cat. No. 5138),
consensus HIV-1 Rev (Cat. No. 6445), SIVmac239 Gag (Cat.
No. 6204), SIV Nef (Cat. No. 6206), HIV-1 Gag (Cat No.
7872–7904), and HIV-1 Nef (Cat No. 5139–5187), all kindly
provided by the AIDS Research and Reagent Program. Pools of
approximately 20 peptides were used in the assays. Env was
divided into 10 and Gag into 5 pools. There were a total of 23,
27, and 21 peptides, respectively, for the Tat, Rev, and Nef, and
each was made into a single pool. Peptide pools were aliquoted
and stored at −80 °C at a concentration of 1 mg/ml. The assay
protocol was reported in detail in an earlier publication (Letvin
et al., 1997). Spots were counted with a stereo-microscope and
reported as the number of spots/106 PBMC.Acknowledgments
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